Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q1 2017 Earnings Presentation
9 slides from Anika Therapeutics's earnings presentation, May 4, 2017
Slide 1: Anika Therapeutics First Quarter 2017 Earnings Call Presentation
ANIKA THERAPEUTICS, INC. First Quarter 2017 Earnings Call Presentation May 4, 2017
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT The statements made in this presentation that are not statements of historical fact are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements involve known a
Slide 3: Expanding Globally
EXPANDING GLOBALLY • Global Revenue Growth of 24% Year-over-Year in Q1 2017 • Commercial Launch in India and Australia Expected in 2H 2017 • Commercial Launch of CINGAL in Canada and Europe Continues • Currently Available in Approximately Ten Countries • Commercial Launch in Germany, U.K., Poland, H
Slide 4: Advancing Pipeline
ADVANCING PIPELINE • 1st Combination Hyaluronic Acid (HA) and Steroid in a Single Injection for Pain Associated with Osteoarthritis (OA) • Submitted CINGAL Investigational New Drug (IND) Application in December 2016 • Finalized Clinical Study Design of 2nd Phase III Trial for U.S. Approval 6-Month
Slide 5: Advancing Pipeline
ADVANCING PIPELINE • Non-woven HA Biodegradable 3D Scaffold for Cartilage Repair • Over 7,000 Treated with HYALOFAST Internationally • FastTRACK Phase III Trial Ongoing for U.S. Approval • Initiated 8 Additional Trial Sites in Austria in 2017 • Expect to Enroll Over 50% of Total Patient Population b
Slide 6: Advancing Pipeline
ADVANCING PIPELINE • Expanding Product Indication for Treatment of Hip OA Pain • IDE Sponsored by U.S. Commercial Partner DePuy Synthes • Potential to be First Therapy to Market for Hip OA Indication • Phase III Trial Ongoing for U.S. Approval 6
Slide 7: Strengthening Infrastructure
STRENGTHENING INFRASTRUCTURE • Integration of Solid HA Manufacturing Operations is Progressing as Planned Currently Completing Quality Checks and Optimizing Production Fully Operational with Regulatory Approvals for Contract Manufacturing Transfer by Year-end 2017 • Completed Build-out of New Eu
Slide 8: Q1 2017 Financial Highlights
Q1 2017 FINANCIAL HIGHLIGHTS Q1 2017 Financial Highlights Q1 2016 Q1 2017 • Total revenue increased 5% year-over-year • MONOVISC revenue grew 24% Total Revenue $22.3 $23.4 year-over-year • Net income of $5.5M for quarter Net Income $6.9 $5.5 • Cash and investments of $139M as of Diluted EPS $0.45 $0
Slide 9: Q&A
Q&A Anika Therapeutics, Inc. First Quarter 2017 Earnings Call Presentation May 4, 2017